Products from BPS Bioscience require a minimum order value above 400€
Background: Folate receptor alpha (FOLR1) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that transports folate (vitamin B9) into cells. FOLR1 is overexpressed in multiple cancers such as cervical cancer, ovarian cancer, breast cancer, and brain carcinomas, and FOLR1 overexpression is associated with poor patient prognosis and increased cancer progression. The overexpression of FOLR1 in a variety of cancerous tissues makes it a valuable target for drug development. There are currently multiple drugs in clinical trials that target FOLR1.
CAS Number: 2407465-18-1
Description: Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.1,2
Format: Aqueous buffer solution.
Purity: ≥90%
Storage Stability: Store at -80°C, protect from light.
Target: FOLR1
Uniprot: P15328
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Keiji Furuuchi, et al. 2021 Cancer Sci. 112(6):2467-2480. 2. Xin Cheng, et al. 2018 Mol Cancer Ther. 17(12):2665-2675.
English
Deutsch
